[Continuous postmenopausal estrogen-progesterone therapy].
In this study menopausal symptoms, endometrial histology, uterine bleeding pattern, plasma lipid concentrations, bone mineral loss, body weight and blood pressure have been evaluated in postmenopausal women who received continuous conjugated equine estrogens and medrogestone over a 1 year treatment period. By the third month of therapy we detected a significant (p < 0.01) improvement in postmenopausal symptomatology. At the 6th and 12th month, endometrial biopsy specimens revealed atrophic endometrium in all women. Uterine bleeding episodes were observed especially during the first months of treatment. Amenorrhoea was found in all patients only after 8 months of therapy. By the 6th month of therapy, we observed a significant (p < 0.01) decrease of plasma cholesterol and low-density lipoprotein cholesterol levels. Instead, plasma high-density lipoprotein and triglycerides concentrations didn't show significant variation from baseline values. No significant changes in bone mineral density could be detected after 12 months of treatment. Body weight and blood pressure were not significantly altered from baseline. This study suggests that continuous conjugated equine estrogens plus medrogestone treatment appears to be an interesting and safe manner to administer postmenopausal hormone replacement therapy. This regimen could represent a good alternative to sequential estroprogestin therapy in women who do not tolerate withdrawal bleeding.
II Facoltà di Medicina e Chirurgia, Istituto di Ginecologia ed Ostetrica, Università degli Studi Federico II, Napoli.
P
P
Affinito
G A
GA
Tommaselli
R
R
Morgera
M
M
Rinaldi
P
P
Di Mauro
C
C
Nappi
D000568:Amenorrhea / Q000139:chemically induced; D001284:Atrophy; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D004714:Endometrial Hyperplasia / Q000473:pathology; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D008524:Medrogestone / Q000008:administration & dosage* / Q000494:pharmacology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal; D014280:Triglycerides / Q000097:blood; D014592:Uterine Hemorrhage / Q000188:drug therapy
D004966:Estrogens, Conjugated (USP); D008074:Lipoproteins; D014280:Triglycerides; D008524:Medrogestone